Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hLF1-11 safety study in autologous hematopoietic stem cell transplant recipients
NL-OMON31209Phase 2Not yet recruiting
- Sponsor
- AM-Pharma
- Start
- Apr 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human lactoferrin peptide 1-11 in bacterial disease and mycoses, sponsored by AM-Pharma. Primary endpoint: Safety and tolerability. Planned start Apr 2007; status: not yet recruiting.
02
Drugs
human lactoferrin peptide 1-11
03
Conditions
bacterial diseasemycoses
Beyond the preview
Go deeper on NL-OMON31209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31209.